KCT0000747已完成未知
A human study to determine effective dose of purple sweet potato extract for investigation of hepatoprotective and antioxidative effects in subject with fatty liver: a randomized, double-blind, placebo-controlled study (Pilot study)
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 o Limit(—)
- 性别
- All
入选标准
- •1) Subject who voluntarily agrees to participate and signs in informed consent form
- •2) Age: = 20 years
- •3) Subject with fatty liver (confirmed by ultrasonography)
排除标准
- •1) BMI = 35kg/m2
- •2) Chronic smoker (= 20 cigarettes/d)
- •3) Alcohol consumption (men: = 30g/d, women: = 15g/d)
- •4) Subject with following diseases and past medical history
- •? Related to Liver Function : viral hepatitis, liver dysfunction, serious liver disease, primary biliary cirrhosis, drug-induced liver disease, autoinnune liver disease, inherited liver disease
- •? General infectious disease (included tuberculosis), serious CVD, renal disease, thyroid disease, autoimmune disease, malignant tumor, multisystem failure, ulcerative colitis, uncontrolled mental illness, HIV
- •5) Received organ transplantation or bone marrow transplantation
- •6) Predicted to use prohibited drugs
- •7) Administration of drugs that affect liver function within 6 months before the first visit (UDCA, statin, hypolipidemic, hypoglycemic, drugs for chronic liver disease, hypotensive, high-dose of estrogen, betaine, corticosteroids, pioglitazone, rosiglitazone, pentoxifylline, gemfibrozil) or administration of steroid over 14 days
- •8) Consumption of dietary supplements or oriental medicine that affect liver function and antioxidative capacity within 8 weeks before the first visit
- •9) Subjects with hypersensitivity to test materials
- •10) Participation in other human study within 12 weeks before the first visit
- •11) Pregnant or lactating women
- •12) Any condition that the principal investigator believes may put the subjects at undue risk
研究者
相似试验
尚未招募
不适用
A clinical study to determine the optimal dose of WIN-1001X by evaluating its efficacy and safety in patients with early Parkinson’s diseaseDiseases of the nervous systemKCT0004536Medihelpline188
已完成
1 期
Clinical trial to examine the effective dose and the safety of [11C]K-2 synthesized by dedicated machine in healthy male volunteersHealthy volunteersJPRN-UMIN000026357Yokohama City University12
已完成
不适用
A human study to evaluate of efficacy and safety of Euglena gracilis powder on immune functioKCT0004406Daesang100
已完成
不适用
A human study to evaluate of efficacy and safety of EFR on immune functioKCT0006255Bundang Jesaeng Hospital100
已完成
不适用
A human study to evaluate safety and effective dose of Seapolynol (Ecklonia cava extract) on postprandial glucose level in healthy subjectsEndocrine, nutritional and metabolic diseaseKCT0001346Ewha Womans University24
